These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 30947649)
1. Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors. Lv X; Tian Y; Li S; Cheng K; Huang X; Kong H; Liao C; Xie Z Curr Med Chem; 2020; 27(32):5429-5443. PubMed ID: 30947649 [TBL] [Abstract][Full Text] [Related]
2. Binding patterns and structure-activity relationship of CDK8 inhibitors. Ma D; Chen X; Shen XB; Sheng LQ; Liu XH Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847 [TBL] [Abstract][Full Text] [Related]
3. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition. Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB Cells; 2019 Nov; 8(11):. PubMed ID: 31717492 [TBL] [Abstract][Full Text] [Related]
4. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? Philip S; Kumarasiri M; Teo T; Yu M; Wang S J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937 [TBL] [Abstract][Full Text] [Related]
5. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives. Ono K; Banno H; Okaniwa M; Hirayama T; Iwamura N; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR Bioorg Med Chem; 2017 Apr; 25(8):2336-2350. PubMed ID: 28302507 [TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer. Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856 [TBL] [Abstract][Full Text] [Related]
8. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential. Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276 [TBL] [Abstract][Full Text] [Related]
9. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer. Offermann A; Joerg V; Becker F; Roesch MC; Kang D; Lemster AL; Tharun L; Behrends J; Merseburger AS; Culig Z; Sailer V; Brägelmann J; Kirfel J; Perner S Am J Pathol; 2022 May; 192(5):813-823. PubMed ID: 35181333 [TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363 [TBL] [Abstract][Full Text] [Related]
12. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors. Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745 [TBL] [Abstract][Full Text] [Related]